Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Leese

Showing results (161-170 of 210) with videos related to

Pageof 21
Sort By:
British Journal of Cancer|October 9, 2008
The in vivo properties of STX243: a potent angiogenesis inhibitor in breast cancerM F C Parsons, P A Foster, S K Chander, et al.
British Journal of Cancer|January 22, 2009
BCRP expression does not result in resistance to STX140 in vivo, despite the increased expression of BCRP in A2780 cells in vitro after long-term STX140 exposureJ M Day, P A Foster, H J Tutill, et al.
BMJ Open Diabetes Research & Care|May 26, 2021
Development and validation of a clinical prediction rule for development of diabetic foot ulceration: an analysis of data from five cohort studiesFrancesca M Chappell, Fay Crawford, Margaret Horne, et al.
Cancer Research|January 7, 2006
The role of 17beta-hydroxysteroid dehydrogenases in modulating the activity of 2-methoxyestradiol in breast cancer cellsSimon P Newman, Christopher R Ireson, Helena J Tutill, et al.
Diabetes Care|July 27, 2011
Achieved levels of HbA1c and likelihood of hospital admission in people with type 1 diabetes in the Scottish population: a study from the Scottish Diabetes Research Network Epidemiology GroupLindsay Govan, Olivia Wu, Andrew Briggs, et al.
The Journal of Steroid Biochemistry and Molecular Biology|November 19, 2003
Steroid sulphatase inhibitors for breast cancer therapyA Purohit, L W L Woo, S K Chander, et al.
British Journal of Cancer|February 19, 2004
Pharmacokinetics and efficacy of 2-methoxyoestradiol and 2-methoxyoestradiol-bis-sulphamate in vivo in rodentsC R Ireson, S K Chander, A Purohit, et al.
Journal of Medicinal Chemistry|December 22, 2006
2-substituted estradiol bis-sulfamates, multitargeted antitumor agents: synthesis, in vitro SAR, protein crystallography, and in vivo activityMathew P Leese, Bertrand Leblond, Andrew Smith, et al.
Biochemical and Biophysical Research Communications|May 28, 2003
Inhibition of carbonic anhydrase II by steroidal and non-steroidal sulphamatesY T Ho, A Purohit, N Vicker, et al.
British Journal of Cancer|November 21, 2007
The therapeutic potential of a series of orally bioavailable anti-angiogenic microtubule disruptors as therapy for hormone-independent prostate and breast cancersS P Newman, P A Foster, Y T Ho, et al.
Pageof 21

Showing results (161-170 of 210) with videos related to

Sort By:
Pageof 21
British Journal of Cancer|October 9, 2008
The in vivo properties of STX243: a potent angiogenesis inhibitor in breast cancerM F C Parsons, P A Foster, S K Chander, et al.
British Journal of Cancer|January 22, 2009
BCRP expression does not result in resistance to STX140 in vivo, despite the increased expression of BCRP in A2780 cells in vitro after long-term STX140 exposureJ M Day, P A Foster, H J Tutill, et al.
BMJ Open Diabetes Research & Care|May 26, 2021
Development and validation of a clinical prediction rule for development of diabetic foot ulceration: an analysis of data from five cohort studiesFrancesca M Chappell, Fay Crawford, Margaret Horne, et al.
Cancer Research|January 7, 2006
The role of 17beta-hydroxysteroid dehydrogenases in modulating the activity of 2-methoxyestradiol in breast cancer cellsSimon P Newman, Christopher R Ireson, Helena J Tutill, et al.
Diabetes Care|July 27, 2011
Achieved levels of HbA1c and likelihood of hospital admission in people with type 1 diabetes in the Scottish population: a study from the Scottish Diabetes Research Network Epidemiology GroupLindsay Govan, Olivia Wu, Andrew Briggs, et al.
The Journal of Steroid Biochemistry and Molecular Biology|November 19, 2003
Steroid sulphatase inhibitors for breast cancer therapyA Purohit, L W L Woo, S K Chander, et al.
British Journal of Cancer|February 19, 2004
Pharmacokinetics and efficacy of 2-methoxyoestradiol and 2-methoxyoestradiol-bis-sulphamate in vivo in rodentsC R Ireson, S K Chander, A Purohit, et al.
Journal of Medicinal Chemistry|December 22, 2006
2-substituted estradiol bis-sulfamates, multitargeted antitumor agents: synthesis, in vitro SAR, protein crystallography, and in vivo activityMathew P Leese, Bertrand Leblond, Andrew Smith, et al.
Biochemical and Biophysical Research Communications|May 28, 2003
Inhibition of carbonic anhydrase II by steroidal and non-steroidal sulphamatesY T Ho, A Purohit, N Vicker, et al.
British Journal of Cancer|November 21, 2007
The therapeutic potential of a series of orally bioavailable anti-angiogenic microtubule disruptors as therapy for hormone-independent prostate and breast cancersS P Newman, P A Foster, Y T Ho, et al.
Pageof 21